Pub Date : 2019-10-24DOI: 10.1097/IJ9.0000000000000076
C. Cui, Xieqiao Yan, Shusen Liu, A. Deitz, L. Si, Z. Chi, X. Sheng, B. Lian, Jian-fang Li, J. Ge, Xuan Wang, L. Mao, B. Tang, Li Zhou, X. Bai, Si-ming Li, Ben Li, Haiyan Wu, Jun Guo
Introduction: Treatment options for advanced melanoma in China are lacking, particularly second-line therapies. The aim of this retrospective observational study was to describe the real-world effectiveness of available anticancer therapies in patients with locally advanced/metastatic melanoma in China. Methods: Adult patients with unresectable stage III or IV melanoma treated between January 1, 2014, and December 31, 2015, at the Beijing Cancer Hospital (BCH) were eligible (data cutoff: December 31, 2017). Data were obtained from patient electronic medical records. Responders were adjudicated per Response Evaluation Criteria in Solid Tumors, version 1.1. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method. Results: Of 248 eligible patients, 221 and 116 were treated with anticancer therapies in first-line and second-line settings, respectively (89 received both at BCH). Approximately 95% of patients had stage IV melanoma; 40.7% had acral melanoma, and 30.6% had mucosal histology. By data cutoff, 195 of 248 (78.6%) patients had died. Median OS for all patients was 10.5 months; 12-month OS rate was 43.9%. In the first-line setting, the objective response rate was 6.3% (95% confidence interval, 3.5%–10.4%) and the median duration of response was 9.1 months. Median PFS was 3.5 months and 12-month PFS rate was 10.6%; median OS was 10.5 months and 12-month OS rate was 43.5%. In the second-line setting, objective response rate was 3.4% (95% confidence interval, 0.9%–8.6%) and median duration of response was 7.5 months. Median PFS was 2.3 months and 12-month PFS rate was 5.2%; median OS was 7.5 months and 12-month OS rate was 30.5%. Conclusion: In China, first-line and second-line anticancer therapy seems to be associated with suboptimal clinical outcomes in advanced melanoma, indicating a need for effective therapies.
{"title":"Real-world clinical outcomes of anticancer treatments in patients with advanced melanoma in China: retrospective, observational study","authors":"C. Cui, Xieqiao Yan, Shusen Liu, A. Deitz, L. Si, Z. Chi, X. Sheng, B. Lian, Jian-fang Li, J. Ge, Xuan Wang, L. Mao, B. Tang, Li Zhou, X. Bai, Si-ming Li, Ben Li, Haiyan Wu, Jun Guo","doi":"10.1097/IJ9.0000000000000076","DOIUrl":"https://doi.org/10.1097/IJ9.0000000000000076","url":null,"abstract":"Introduction: Treatment options for advanced melanoma in China are lacking, particularly second-line therapies. The aim of this retrospective observational study was to describe the real-world effectiveness of available anticancer therapies in patients with locally advanced/metastatic melanoma in China. Methods: Adult patients with unresectable stage III or IV melanoma treated between January 1, 2014, and December 31, 2015, at the Beijing Cancer Hospital (BCH) were eligible (data cutoff: December 31, 2017). Data were obtained from patient electronic medical records. Responders were adjudicated per Response Evaluation Criteria in Solid Tumors, version 1.1. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method. Results: Of 248 eligible patients, 221 and 116 were treated with anticancer therapies in first-line and second-line settings, respectively (89 received both at BCH). Approximately 95% of patients had stage IV melanoma; 40.7% had acral melanoma, and 30.6% had mucosal histology. By data cutoff, 195 of 248 (78.6%) patients had died. Median OS for all patients was 10.5 months; 12-month OS rate was 43.9%. In the first-line setting, the objective response rate was 6.3% (95% confidence interval, 3.5%–10.4%) and the median duration of response was 9.1 months. Median PFS was 3.5 months and 12-month PFS rate was 10.6%; median OS was 10.5 months and 12-month OS rate was 43.5%. In the second-line setting, objective response rate was 3.4% (95% confidence interval, 0.9%–8.6%) and median duration of response was 7.5 months. Median PFS was 2.3 months and 12-month PFS rate was 5.2%; median OS was 7.5 months and 12-month OS rate was 30.5%. Conclusion: In China, first-line and second-line anticancer therapy seems to be associated with suboptimal clinical outcomes in advanced melanoma, indicating a need for effective therapies.","PeriodicalId":42930,"journal":{"name":"International Journal of Surgery-Oncology","volume":"115 1","pages":"e76 - e76"},"PeriodicalIF":0.3,"publicationDate":"2019-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77549607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-10-18DOI: 10.1097/ij9.0000000000000078
T. König, O. Muensterer
According to the World Health Organization, the global decrease of physical activity is one of the leading causes of mortality worldwide, resulting not only in cardiopulmonary disease and obesity, but also in a predisposition for the development of cancer [1] . This article gives an up-date perspective on the impact of sedentary behavior and exercise on cancer development, course of treatment, as well as secondary prevention in cancer survivors. colorectal and is clear in large epidemiological series, risk reduction
{"title":"Sedentary behavior, exercise, and cancer development","authors":"T. König, O. Muensterer","doi":"10.1097/ij9.0000000000000078","DOIUrl":"https://doi.org/10.1097/ij9.0000000000000078","url":null,"abstract":"According to the World Health Organization, the global decrease of physical activity is one of the leading causes of mortality worldwide, resulting not only in cardiopulmonary disease and obesity, but also in a predisposition for the development of cancer [1] . This article gives an up-date perspective on the impact of sedentary behavior and exercise on cancer development, course of treatment, as well as secondary prevention in cancer survivors. colorectal and is clear in large epidemiological series, risk reduction","PeriodicalId":42930,"journal":{"name":"International Journal of Surgery-Oncology","volume":"51 1","pages":""},"PeriodicalIF":0.3,"publicationDate":"2019-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76811620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-10-01DOI: 10.1097/IJ9.0000000000000077
Jan Goedeke, O. Muensterer
Being overweight has been a long-known peril to health, and scientists were able to show a relationship between body fat and cancer years ago. Of course, not every obese individual will inevitably develop cancer, but recent scientific studies show that excessive body fat has an impact on a much broader spectrum of cancers than previously thought. This applies to adults as well as children and adolescents. In 2015, the Organisation for Economic Co-operation and Development (OECD) reported that already > 50%of adults and nearly 30% of teenagers in 34 member countries were considered overweight (body mass index, BMI ≥ 25 kg/m2 body surface area), or even obese (BMI ≥30 kg/m2 body surface area). The tendency increased gradually in all countries over a period of 25 years (1990–2015).We therefore have to expect steadily rising numbers of cancers worldwide solely due to obesity in the future. A population-based study using BMI and cancer incidence data from the GLOBOCAN project estimated that, in 2012 in the United States, about 28,000 new cases of cancer in men (3.5%) and 72,000 in women (9.5%) were due to overweight or obesity. The percentage of cases attributed to overweight or obesity varied widely for different cancer types but was as high as 54% for gallbladder cancer in women and 44% for esophageal adenocarcinoma in men. The International Agency for Research on Cancer (IARC) as part of the World Health Organization (WHO) in 2016 reported an increased risk of cancer for at least 13 cancer types [colon cancer, esophageal cancer, renal carcinoma, uterine cancer, breast cancer (during and after menopause; also in men), liver cancer, pancreatic cancer, gall bladder cancer, ovarian cancer, gastric cancer, thyroid cancer, multiple myeloma, and meningioma]. For some of these cancers, the experts even found a dose-response relationship, implying that the risk of cancer increases with BMI. Currently, there are many theories that could explain the increased incidence of cancer in obesity. The preponderance of the evidence suggests that a combination of different factors might be responsible. However, it should be reiterated that there is no direct link between obesity and the development of cancer. On the one hand, obesity seems to cause a general hormonal imbalance including hyperinsulinemia and an increase in insulinlike growth factors, as well as sex hormones. In addition, hyperplastic and hypertrophic white adipose tissue (especially visceral adipose tissue) acts as an independent active endocrine organ releasing immunologically active adipokines and other hormones. These hormonal imbalances support cell growth– promoting processes. On the other hand, obesity is associated with a state of low-grade chronic inflammation. Insulin resistance and the metabolic syndrome are associated with higher circulating concentrations of inflammation-related markers, including leptin, interleukin-6, and tumor necrosis factor, many of which have been shown to enhance tum
{"title":"The role of obesity in cancer development","authors":"Jan Goedeke, O. Muensterer","doi":"10.1097/IJ9.0000000000000077","DOIUrl":"https://doi.org/10.1097/IJ9.0000000000000077","url":null,"abstract":"Being overweight has been a long-known peril to health, and scientists were able to show a relationship between body fat and cancer years ago. Of course, not every obese individual will inevitably develop cancer, but recent scientific studies show that excessive body fat has an impact on a much broader spectrum of cancers than previously thought. This applies to adults as well as children and adolescents. In 2015, the Organisation for Economic Co-operation and Development (OECD) reported that already > 50%of adults and nearly 30% of teenagers in 34 member countries were considered overweight (body mass index, BMI ≥ 25 kg/m2 body surface area), or even obese (BMI ≥30 kg/m2 body surface area). The tendency increased gradually in all countries over a period of 25 years (1990–2015).We therefore have to expect steadily rising numbers of cancers worldwide solely due to obesity in the future. A population-based study using BMI and cancer incidence data from the GLOBOCAN project estimated that, in 2012 in the United States, about 28,000 new cases of cancer in men (3.5%) and 72,000 in women (9.5%) were due to overweight or obesity. The percentage of cases attributed to overweight or obesity varied widely for different cancer types but was as high as 54% for gallbladder cancer in women and 44% for esophageal adenocarcinoma in men. The International Agency for Research on Cancer (IARC) as part of the World Health Organization (WHO) in 2016 reported an increased risk of cancer for at least 13 cancer types [colon cancer, esophageal cancer, renal carcinoma, uterine cancer, breast cancer (during and after menopause; also in men), liver cancer, pancreatic cancer, gall bladder cancer, ovarian cancer, gastric cancer, thyroid cancer, multiple myeloma, and meningioma]. For some of these cancers, the experts even found a dose-response relationship, implying that the risk of cancer increases with BMI. Currently, there are many theories that could explain the increased incidence of cancer in obesity. The preponderance of the evidence suggests that a combination of different factors might be responsible. However, it should be reiterated that there is no direct link between obesity and the development of cancer. On the one hand, obesity seems to cause a general hormonal imbalance including hyperinsulinemia and an increase in insulinlike growth factors, as well as sex hormones. In addition, hyperplastic and hypertrophic white adipose tissue (especially visceral adipose tissue) acts as an independent active endocrine organ releasing immunologically active adipokines and other hormones. These hormonal imbalances support cell growth– promoting processes. On the other hand, obesity is associated with a state of low-grade chronic inflammation. Insulin resistance and the metabolic syndrome are associated with higher circulating concentrations of inflammation-related markers, including leptin, interleukin-6, and tumor necrosis factor, many of which have been shown to enhance tum","PeriodicalId":42930,"journal":{"name":"International Journal of Surgery-Oncology","volume":"434 1","pages":"e77 - e77"},"PeriodicalIF":0.3,"publicationDate":"2019-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85754968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-09-01DOI: 10.1097/ij9.0000000000000075
I. Janmohamed
{"title":"A medical student’s reflection on intercalation","authors":"I. Janmohamed","doi":"10.1097/ij9.0000000000000075","DOIUrl":"https://doi.org/10.1097/ij9.0000000000000075","url":null,"abstract":"","PeriodicalId":42930,"journal":{"name":"International Journal of Surgery-Oncology","volume":"47 10 1","pages":""},"PeriodicalIF":0.3,"publicationDate":"2019-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77289380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-08-01DOI: 10.1097/IJ9.0000000000000071
Shahryar Noordin, T. Ahmad, M. Umer, S. Allana, Kiran Hilal, N. Uddin, P. Hashmi
{"title":"Aneurysmal bone cyst of the pelvis and extremities: Contemporary\u0000 management","authors":"Shahryar Noordin, T. Ahmad, M. Umer, S. Allana, Kiran Hilal, N. Uddin, P. Hashmi","doi":"10.1097/IJ9.0000000000000071","DOIUrl":"https://doi.org/10.1097/IJ9.0000000000000071","url":null,"abstract":"","PeriodicalId":42930,"journal":{"name":"International Journal of Surgery-Oncology","volume":"8 1","pages":""},"PeriodicalIF":0.3,"publicationDate":"2019-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84781086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-06-01DOI: 10.1097/IJ9.0000000000000074
T. Yasui, Tatsuya Suzuki, M. Urano, S. Tahara, M. Kuroda, F. Hara, Shunsuke Watanabe, N. Uga, A. Naoe, Y. Kondo, T. Tuchiya
{"title":"Radiologic complications in a long-term survivor with Wilms tumor: a case\u0000 report","authors":"T. Yasui, Tatsuya Suzuki, M. Urano, S. Tahara, M. Kuroda, F. Hara, Shunsuke Watanabe, N. Uga, A. Naoe, Y. Kondo, T. Tuchiya","doi":"10.1097/IJ9.0000000000000074","DOIUrl":"https://doi.org/10.1097/IJ9.0000000000000074","url":null,"abstract":"","PeriodicalId":42930,"journal":{"name":"International Journal of Surgery-Oncology","volume":"27 1","pages":""},"PeriodicalIF":0.3,"publicationDate":"2019-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75322718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-03-01DOI: 10.1097/IJ9.0000000000000072
K. Kashiwabara, H. Semba, S. Fujii, S. Tsumura
Introduction: Anticancer therapy for disease recurrence in medically inoperable stage I lung adenocarcinoma patients receiving stereotactic body radiotherapy (SBRT) has not been previously reported. Gefitinib is tolerable and effective in patients with active epidermal growth factor receptor (EGFR) mutations who have an advanced age and/or a low performance status, but whether gefitinib improves the survival of such patients with disease recurrence after SBRT remains unclear. Patients and methods: We retrospectively evaluated overall survival after disease recurrence in patients with active EGFR mutations who received gefitinib (GEF group) and patients without active EGFR mutations who did not receive gefitinib (non-GEF group). Results: During a follow-up period with a median time of 36.0 months, disease recurrence occurred in 10 of 20 patients with medically inoperable stage I lung adenocarcinoma who received SBRT (2 cases with local tumor recurrence alone and 8 cases with lymph node and/or distant metastasis). The median age or the median Charlson comorbidity index score were 84 years and 2 in the GEF group (n=4) and 81 years and 2 in the non-GEF group (n=6), respectively. Two cases in the GEF group received chemotherapy after first-line gefitinib therapy. Two cases in the non-GEF group received chemotherapy, but the others received best supportive care alone. The median overall survival time from disease recurrence was significantly different between the 2 groups (27.3 vs. 3.6 mo, P=0.038). Two cases with grade 2 radiation pneumonitis did not have a recurrence of pneumonitis during gefitinib therapy. Conclusions: Gefitinib might be useful as a salvage therapy in patients who desire to continue anticancer treatment.
{"title":"Outcomes of gefitinib therapy for disease recurrence in medically inoperable stage I lung adenocarcinoma patients with active EGFR mutations receiving stereotactic body radiotherapy: a single-institute retrospective study","authors":"K. Kashiwabara, H. Semba, S. Fujii, S. Tsumura","doi":"10.1097/IJ9.0000000000000072","DOIUrl":"https://doi.org/10.1097/IJ9.0000000000000072","url":null,"abstract":"Introduction: Anticancer therapy for disease recurrence in medically inoperable stage I lung adenocarcinoma patients receiving stereotactic body radiotherapy (SBRT) has not been previously reported. Gefitinib is tolerable and effective in patients with active epidermal growth factor receptor (EGFR) mutations who have an advanced age and/or a low performance status, but whether gefitinib improves the survival of such patients with disease recurrence after SBRT remains unclear. Patients and methods: We retrospectively evaluated overall survival after disease recurrence in patients with active EGFR mutations who received gefitinib (GEF group) and patients without active EGFR mutations who did not receive gefitinib (non-GEF group). Results: During a follow-up period with a median time of 36.0 months, disease recurrence occurred in 10 of 20 patients with medically inoperable stage I lung adenocarcinoma who received SBRT (2 cases with local tumor recurrence alone and 8 cases with lymph node and/or distant metastasis). The median age or the median Charlson comorbidity index score were 84 years and 2 in the GEF group (n=4) and 81 years and 2 in the non-GEF group (n=6), respectively. Two cases in the GEF group received chemotherapy after first-line gefitinib therapy. Two cases in the non-GEF group received chemotherapy, but the others received best supportive care alone. The median overall survival time from disease recurrence was significantly different between the 2 groups (27.3 vs. 3.6 mo, P=0.038). Two cases with grade 2 radiation pneumonitis did not have a recurrence of pneumonitis during gefitinib therapy. Conclusions: Gefitinib might be useful as a salvage therapy in patients who desire to continue anticancer treatment.","PeriodicalId":42930,"journal":{"name":"International Journal of Surgery-Oncology","volume":"112 1","pages":"e72"},"PeriodicalIF":0.3,"publicationDate":"2019-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81012851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-09-01DOI: 10.1097/ij9.0000000000000065
J. Davies, F. Al-Hassani, R. Kannan
Facial nerve disorders present with varying levels of facial dysfunction. Facial nerve reinnervation techniques aim to correct this by attempting to reestablish the connection lost between the facial nerve nucleus and its distal branches, or by using donor nerves to provide an alternate neural input to the facial nerve. Many facial nerve disorders exist; however, tumors and trauma to the facial nerve are the 2 causes that most commonly result in the patient being considered for reanimation procedures, as they most often result in facial nerve discontinuity. Reinnervation techniques are the first line surgical intervention for facial paralysis when a direct connection between the facial nerve cannot be reestablished, with the XII-VII nerve transfer being the most reliable and having the most predictable outcome when compared with the alternative VII-VII procedure. However, when the reinnervation time window is missed, other techniques of reanimation must be used in an attempt to best restore the normal symmetry and function of the face. The modifications to the XII-VII nerve transfer technique have made it the most popular of all methods; however, there are still many other nerves that may be considered as donors, giving the surgeon other options in the event of the hypoglossal (XIIth) nerve being unsuitable.
{"title":"Facial nerve disorder: a review of the literature","authors":"J. Davies, F. Al-Hassani, R. Kannan","doi":"10.1097/ij9.0000000000000065","DOIUrl":"https://doi.org/10.1097/ij9.0000000000000065","url":null,"abstract":"Facial nerve disorders present with varying levels of facial dysfunction. Facial nerve reinnervation techniques aim to correct this by attempting to reestablish the connection lost between the facial nerve nucleus and its distal branches, or by using donor nerves to provide an alternate neural input to the facial nerve. Many facial nerve disorders exist; however, tumors and trauma to the facial nerve are the 2 causes that most commonly result in the patient being considered for reanimation procedures, as they most often result in facial nerve discontinuity. Reinnervation techniques are the first line surgical intervention for facial paralysis when a direct connection between the facial nerve cannot be reestablished, with the XII-VII nerve transfer being the most reliable and having the most predictable outcome when compared with the alternative VII-VII procedure. However, when the reinnervation time window is missed, other techniques of reanimation must be used in an attempt to best restore the normal symmetry and function of the face. The modifications to the XII-VII nerve transfer technique have made it the most popular of all methods; however, there are still many other nerves that may be considered as donors, giving the surgeon other options in the event of the hypoglossal (XIIth) nerve being unsuitable.","PeriodicalId":42930,"journal":{"name":"International Journal of Surgery-Oncology","volume":"69 ","pages":""},"PeriodicalIF":0.3,"publicationDate":"2018-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/ij9.0000000000000065","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72429211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-06-01DOI: 10.1097/IJ9.0000000000000067
M. J. Kim, C. Kim, Je Kim, Young Sam Park
Background and Objective: Because of the high survival rate and low recurrence rate of thyroid carcinoma, the therapeutic process is changing from aggressive treatment to submissive treatment. Currently, choosing central node dissection (CND) as a treatment option is considered controversial since. This approach has been shown to have poor outcomes. Therefore, we conducted this study to confirm whether the intraoperative frozen section analysis (IFSA) of CND during surgery affects treatment outcomes of patients with this type of cancer. Materials and Methods: First, we collected the medical records of 265 patients who underwent surgery for papillary thyroid cancer at the Presbyterian Medical Center from 2014 to 2016. The patients were divided into 2 groups: IFSA and non-IFSA. The outcomes of treatment options were then assessed. We analyzed the sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of IFSA of CND. Results: Of the 265 patients in the study, 74 patients (89%) in the IFSA group and 95 patients (52.2%) in the non-IFSA group were treated appropriately (P-value=0.000). The sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of IFSA of CND were 93.5%, 100%, 100%, 96.3%, and 97.5%, respectively. Conclusions: The IFSA of CND is a useful method to confirm central node metastasis during surgery. Determining the range of surgery required for each patient using this method is useful for ensuring minimal complications and for providing a successful, effective oncologic surgery.
{"title":"Efficiency of intraoperative frozen section analysis of central neck lymph node dissection in patients with papillary thyroid carcinoma","authors":"M. J. Kim, C. Kim, Je Kim, Young Sam Park","doi":"10.1097/IJ9.0000000000000067","DOIUrl":"https://doi.org/10.1097/IJ9.0000000000000067","url":null,"abstract":"Background and Objective: Because of the high survival rate and low recurrence rate of thyroid carcinoma, the therapeutic process is changing from aggressive treatment to submissive treatment. Currently, choosing central node dissection (CND) as a treatment option is considered controversial since. This approach has been shown to have poor outcomes. Therefore, we conducted this study to confirm whether the intraoperative frozen section analysis (IFSA) of CND during surgery affects treatment outcomes of patients with this type of cancer. Materials and Methods: First, we collected the medical records of 265 patients who underwent surgery for papillary thyroid cancer at the Presbyterian Medical Center from 2014 to 2016. The patients were divided into 2 groups: IFSA and non-IFSA. The outcomes of treatment options were then assessed. We analyzed the sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of IFSA of CND. Results: Of the 265 patients in the study, 74 patients (89%) in the IFSA group and 95 patients (52.2%) in the non-IFSA group were treated appropriately (P-value=0.000). The sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of IFSA of CND were 93.5%, 100%, 100%, 96.3%, and 97.5%, respectively. Conclusions: The IFSA of CND is a useful method to confirm central node metastasis during surgery. Determining the range of surgery required for each patient using this method is useful for ensuring minimal complications and for providing a successful, effective oncologic surgery.","PeriodicalId":42930,"journal":{"name":"International Journal of Surgery-Oncology","volume":"AES-8 1","pages":"e67"},"PeriodicalIF":0.3,"publicationDate":"2018-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84505546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-06-01DOI: 10.1097/IJ9.0000000000000068
Cheng Wang, Bing Yang, Yali Wu, Li Tan, Zongxi Sun, Junming Ma, Yang Lu, S. Du
Shenqi Fuzheng (SQFZ) is a traditional Chinese medicine injection for lung cancer that is commonly used in China. It can significantly improve the immunity of patients after chemotherapy and reduce adverse reactions of chemotherapy. In the present study, we pay attention to whether it showed a direct synergistic effect with commonly used chemotherapy drugs, and combined SQFZ with docetaxel to study the effect on cell proliferation of lung carcinoma cell lines, A549 and mouse lung cancer cell. Four-part experiments were used to study the effects of monotherapy and combined pharmacotherapy of these 2 medicines: (1) Thiazolan experiment test on the cellular toxicity effect, (2) the cellular morphology change after administration under confocal microscopy, (3) the inhibitory effect of the 2 drugs on the invasion and migration of lung cancer, and (4) the influence on apoptosis of 2 studied cell lines. The results showed that SQFZ had no cell growth inhibitory effect (Thiazolan experiment) when used alone, whereas when used in combination, it could significantly enhance the cell growth inhibitory effect of lower concentrations of docetaxel. There was obvious difference between the effects of docetaxel alone and that of combination of the 2 drugs in cell morphology from the degree of cell fragmentation, and it also showed significant synergistic effect on docetaxel (0.8–80 &mgr;g/L) on cell migration and apoptosis. These results demonstrated that applying SQFZ as an adjuvant of chemotherapeutic drugs to treat cancer has the clinical significance of reducing toxicity and increasing curative effect.
{"title":"Study on antilung cancer synergistic effect of Shenqi Fuzheng combined with docetaxel","authors":"Cheng Wang, Bing Yang, Yali Wu, Li Tan, Zongxi Sun, Junming Ma, Yang Lu, S. Du","doi":"10.1097/IJ9.0000000000000068","DOIUrl":"https://doi.org/10.1097/IJ9.0000000000000068","url":null,"abstract":"Shenqi Fuzheng (SQFZ) is a traditional Chinese medicine injection for lung cancer that is commonly used in China. It can significantly improve the immunity of patients after chemotherapy and reduce adverse reactions of chemotherapy. In the present study, we pay attention to whether it showed a direct synergistic effect with commonly used chemotherapy drugs, and combined SQFZ with docetaxel to study the effect on cell proliferation of lung carcinoma cell lines, A549 and mouse lung cancer cell. Four-part experiments were used to study the effects of monotherapy and combined pharmacotherapy of these 2 medicines: (1) Thiazolan experiment test on the cellular toxicity effect, (2) the cellular morphology change after administration under confocal microscopy, (3) the inhibitory effect of the 2 drugs on the invasion and migration of lung cancer, and (4) the influence on apoptosis of 2 studied cell lines. The results showed that SQFZ had no cell growth inhibitory effect (Thiazolan experiment) when used alone, whereas when used in combination, it could significantly enhance the cell growth inhibitory effect of lower concentrations of docetaxel. There was obvious difference between the effects of docetaxel alone and that of combination of the 2 drugs in cell morphology from the degree of cell fragmentation, and it also showed significant synergistic effect on docetaxel (0.8–80 &mgr;g/L) on cell migration and apoptosis. These results demonstrated that applying SQFZ as an adjuvant of chemotherapeutic drugs to treat cancer has the clinical significance of reducing toxicity and increasing curative effect.","PeriodicalId":42930,"journal":{"name":"International Journal of Surgery-Oncology","volume":"1 1","pages":"e68"},"PeriodicalIF":0.3,"publicationDate":"2018-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89610756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：